$PFE

PFIZER INC

CIK:0000078003|SEC Filings
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Alliance revenues $ 2,339 $ 2,113
Total revenues 14,451 13,715
Costs and expenses:    
Cost of sales [1] 3,548 2,845
Selling, informational and administrative expenses [1] 2,961 3,031
Research and development expenses [1] 2,490 2,203
Acquired in-process research and development expenses 137 9
Amortization of intangible assets 1,183 1,211
Restructuring charges and certain acquisition-related costs 100 678
Other (income)/deductions––net 861 953
Income from continuing operations before provision/(benefit) for taxes on income [2] 3,170 2,785
Provision/(benefit) for taxes on income 461 (189)
Income from continuing operations 2,709 2,973
Discontinued operations––net of tax (13) 0
Net income before allocation to noncontrolling interests 2,696 2,973
Less: Net income attributable to noncontrolling interests 8 6
Net income attributable to Pfizer Inc. common shareholders $ 2,687 $ 2,967
Earnings per common share––basic:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.48 $ 0.52
Discontinued operations––net of tax (in dollars per share) 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.47 0.52
Earnings per common share––diluted:    
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.47 0.52
Discontinued operations––net of tax (in dollars per share) 0 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.47 $ 0.52
Weighted-average shares--basic (in shares) 5,691 5,675
Weighted-average shares--diluted (in shares) 5,731 5,710
Product [Member]    
Revenues $ 11,715 $ 11,294
Royalty [Member]    
Revenues $ 396 $ 308
[1] Exclusive of amortization of intangible assets.
[2] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.